Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring.
OBJECTIVE
To assess differences in activity and immobility during sleep between patients with Parkinson's disease (PD) and healthy subjects and to evaluate the relations of clinical variables with the motor activity measures in patients with PD.


METHODS
Survey, case series.


METHODS
University hospital outpatient neurology department and urban population in Leiden, the Netherlands. Motor activity was recorded during 6 successive nights at home with a wrist-worn activity monitor.


METHODS
Eighty-nine patients with PD and 83 age-matched healthy controls.


METHODS
For each subject, three mean measures reflecting activity or immobility during the nocturnal period were calculated.


RESULTS
Compared with the healthy elderly subjects, patients with PD have an elevated nocturnal activity level and an increased proportion of time with movement, indicating a more disturbed sleep. The mean duration of nocturnal immobility periods was similar for both groups. This measure, however, did reflect the self-reported disturbed sleep maintenance in both groups. The daily dose of levodopa or the use of dopamine agonists in patients not receiving levodopa, rather than disease severity, proved to be the best predictors of nocturnal activity.


CONCLUSIONS
We hypothesize that in mildly to moderately affected patients with PD, levodopa or dopamine agonists cause sleep disruption by their effects on sleep regulation. In more severely affected patients, the beneficial effects of these drugs on nocturnal disabilities that cause sleep disruption in PD prevail.
van Hilten
B
B
Department of Neurology, Academic Hospital, Leiden, The Netherlands.
Hoff
J I
JI
Middelkoop
H A
HA
van der Velde
E A
EA
Kerkhof
G A
GA
Wauquier
A
A
Kamphuisen
H A
HA
Roos
R A
RA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009043:Motor Activity; D009068:Movement; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D012893:Sleep Wake Disorders / Q000209:etiology* / Q000503:physiopathology*
D000978:Antiparkinson Agents